uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data

• click to rate

  Posted by Two Blokes May 8 - Filed in Stock - 4 views
  
  uniQure's lead program for Huntington's Disease is planning to file an application via the accelerated approval pathway. On Monday, May 5th, PTC Therapeutics announced positive results from their phase 2 Huntington's Disease trial. I compare the data from these two treatments and share my thoughts here.